VTRS

Viatris
D

VTRS

10.645
USD
-0.06
(-0.51%)
Market Closed
Volume
171,374
EPS
2
Div Yield
4.51
P/E
-4
Market Cap
12,410,708,792
Related Instruments
ABBV
ABBV
1.105
(0.53%)
210.630 USD
AZN
AZN
0.510
(0.63%)
80.970 USD
BMY
BMY
-0.520
(-1.07%)
47.890 USD
GSK
GSK
0.100
(0.25%)
40.190 USD
JNJ
JNJ
0.230
(0.13%)
179.250 USD
MRK
MRK
1.235
(1.43%)
87.370 USD
PFE
PFE
0.155
(0.60%)
25.870 USD
P
PRGO
1.050
(4.48%)
24.490 USD
REGN
REGN
-8.70
(-1.45%)
589.55 USD
More
News

Title: Viatris

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.